Quintarabio

What Quintarabio does

Quintara Biosciences (legal entity: Quintara Biosciences Inc.) is a US-based biotechnology services company founded in 2005 in California and now operating five labs across Hayward and Culver City (CA), Watertown (MA), Sugar Land/Houston (TX), and San Diego (CA), following the 2026 relocation of its Boston-area laboratory. The company provides an integrated DNA services platform organized around four technology pillars: DNA Reading (Sanger, Illumina NGS, Oxford Nanopore long-read, and PacBio sequencing), DNA Writing (oligo and gene synthesis under the Abgene brand), DNA Production (plasmid preparation and custom cloning), and DNA Expression (recombinant and bispecific antibodies, IVT mRNA synthesis with FTO IP options, and microfluidic LNP encapsulation including antibody-conjugated targeted LNPs). Proprietary technology elements include the QuinDye™ Terminator reagent kit and a validated mRNA-LNP workflow with 98% capping efficiency, 90%+ LNP encapsulation efficiency, and documented use in 20+ IND-directed programs.

Revenue is generated almost entirely through transactional per-sample and per-gene pricing under a direct-to-consumer model: the QuinGo online ordering portal at order.quintarabio.com handles self-serve orders, supported by inside and field sales managers for enterprise accounts. Public price points are aggressive — $3-5 for Sanger and Nanopore whole-plasmid/amplicon sequencing, $49 for short gene synthesis, $99 for bulk RNA-seq, with bundle discounts and flash-sale promotions designed to drive volume. A nationwide network of 1,000+ free drop boxes with same-day courier pickup in select markets (Cambridge/Boston) functions as the primary sample logistics backbone. Customer segments are explicitly horizontal, spanning academic researchers (UC-Davis, MIT, Broad Institute, HHMI, Whitehead, NIH), biotech and pharma R&D groups, mRNA therapeutics developers, and single-cell research teams, with no disclosed enterprise contracts or ARR figures. Strategic positioning in 2025-2026 has shifted toward aggressive product launches (WPS-Express, AmpValue, mRNA/LNP services), a major acquisition (Laragen from Transnetyx, September 2025), and facility expansion, while maintaining a value-priced, transactional GTM anchored on rapid turnaround and nationwide reach.

Name

Quintarabio

Legal name

Quintara Biosciences Inc.

Website

https://quintarabio.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Quintara Biosciences is a US biotech services company that provides integrated DNA sequencing (Sanger, Illumina, Nanopore, PacBio), gene synthesis, mRNA/LNP, and antibody expression to academic researchers, biotech, and pharma customers nationwide via a direct-to-consumer online portal and 1,000+ drop boxes.

Ownership category

akta.pro rank

Product category

DNA Sequencing and Molecular Biology Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

akta.pro secondary industry

Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE)

Keywords

• DNA sequencing services
• Gene synthesis
• Plasmid preparation
• IVT mRNA synthesis
• LNP encapsulation

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Sequencing Services: Core revenue stream from DNA sequencing services including Sanger sequencing, Nanopore sequencing (whole plasmid, amplicon), NGS/Illumina sequencing (bulk RNA-seq, AmpExp amplicon, single-cell), and PacBio sequencing. Services offered at per-sample unit pricing with volume discounts and promotional pricing.
2. Molecular Biology Services: Gene synthesis (Abgene), custom cloning, plasmid preparation, and oligo synthesis services. Revenue generated at per-gene or per-reaction unit pricing with tiered pricing based on sequence length and turnaround time.
3. mRNA Synthesis & LNP Services: IVT mRNA synthesis services at tiered quality grades (Screening, Research, Preclinical) with scales from 0.2mg to 100mg+, plus LNP encapsulation services with bundle discounts (10-15% off for mRNA+LNP bundles).
4. Antibody/Protein Expression: Recombinant antibody and protein services including HTP recombinant antibody and bi-specific antibody expression for research and preclinical applications.
5. Reagent Products: Sale of proprietary reagent products including QuinDye™ Terminator Kit for Sanger sequencing reactions, providing premixed reagents for customer self-service.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Quintara Biosciences is a fee-for-service DNA services provider that performs Sanger, Next-Generation (Illumina), Nanopore, and PacBio sequencing; custom gene synthesis (Abgene); custom cloning; plasmid preparation; recombinant antibody and bispecific antibody expression; IVT mRNA synthesis; and LNP encapsulation for academic and biotech/pharma customers. It complements these services with proprietary reagents such as the QuinDye™ Terminator kit and delivers results through its QuinGo online portal, nationwide drop box logistics, and five US service labs.

Product overview

Quintara Biosciences offers an integrated DNA services platform organized around four key technology pillars: DNA Reading (Sanger, NGS, Nanopore, and PacBio sequencing), DNA Writing (oligo and gene synthesis including Abgene), DNA Production (plasmid preparation), and DNA Expression (recombinant antibodies and proteins). The core sequencing services span from traditional Sanger sequencing at $3-4/sample through Next Generation Sequencing (NGS) using Illumina and 10x Genomics platforms for bulk RNA-seq, amplicon sequencing, and single-cell analysis, to third-generation Nanopore long-read sequencing with tiered offerings including Whole Plasmid Sequencing (WPS Express/Standard/Pro) and Amplicon Sequencing (AmpValue/AmpStandard/AmpPro). The molecular biology portfolio includes Abgene gene synthesis ($49/gene), custom cloning, plasmid preparation, HTP/bispecific antibodies, and mRNA services including IVT synthesis and LNP encapsulation. The company also offers QuinDye™ Terminator as a reagent product. Services are delivered through five U.S. locations (Boston, San Francisco, Houston, Los Angeles, San Diego) with nationwide drop boxes and online ordering via the QuinGo portal.

Differentiator

Problem solved

Functional benefit

Brands

• QuinDye™ Terminator: QuinDye™ Terminator Kit provides premixed reagents for Sanger sequencing reactions, including Dye Terminator and 5x buffer, formulated to deliver long, high-quality reads with uniform peak heights.
• AmpValue
• WPS-Express
• Abgene
• AmpExpress
• QuinGo

Products and services

• Sanger Sequencing Traditional capillary DNA sequencing service used by academic and biotech customers for validating shorter DNA fragments, plasmid inserts, and CRISPR edits, priced at $3-$4 per sample with overnight turnaround via the QuinGo ordering portal.
• Next Generation Sequencing (NGS) Illumina-based high-throughput sequencing service including bulk RNA-seq (from $99/sample), AmpExpress amplicon sequencing (from $29.90/sample), and 10x Genomics Chromium X single-cell sequencing for researchers requiring transcriptome-wide or targeted genomic analysis.
• Nanopore Sequencing Third-generation Oxford Nanopore long-read sequencing service using R10.4.1 chemistry with AI basecalling, covering whole plasmid sequencing and full-length amplicon sequencing for customers needing long-read, primer-free verification of plasmids up to 25kb and amplicons from 200bp to 25kb, with flat-rate pricing starting at $4.99/sample.
• Abgene Gene Synthesis Custom gene synthesis service offering $49 per gene launch pricing for sequences up to 800bp with 4 business day turnaround, using an FTO plasmid backbone, for molecular biology and synthetic biology researchers.
• Custom Cloning Molecular biology cloning service integrated with Quintara's gene synthesis and plasmid preparation workflows for researchers building constructs.
• Plasmid Preparation High-quality plasmid DNA preparation service with 100% full-sequence accuracy and guaranteed yield, including the QuinUP Plasmid offering, for research and preclinical applications.
• HTP Recombinant Antibody High-throughput recombinant antibody expression service for protein production applications serving research and biotech customers.
• Bi-specific Antibody Bispecific antibody development and production service for research and preclinical applications.
• IVT mRNA Synthesis Service In vitro transcription mRNA synthesis with three quality grades (Screening, Research, Preclinical), optimized dsRNA control (<0.1%), capping efficiency up to 98%, endotoxin below 10 EU/mg, supporting saRNA and modified NTPs for vaccine, immunotherapy, and gene editing programs.
• LNP Encapsulation Service Microfluidic lipid nanoparticle encapsulation for mRNA delivery with average encapsulation efficiency above 90%, PDI as low as 0.1, optional antibody-conjugated targeted LNP (Ab-tLNP) capability, and bundle discounts with IVT mRNA synthesis for research and preclinical programs.
• QuinDye™ Terminator Reagent Kit Proprietary premixed reagent kit for Sanger sequencing reactions, including Dye Terminator and 5x buffer, formulated to deliver long high-quality reads with uniform peak heights and efficient resolution of complex sequencing structures; free sample available to researchers.

Quantifiable outcome

• 98% capping efficiency for IVT mRNA
• +7 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered major, minor and core.

• Transnetyx (Laragen Sanger Sequencing)majorStrategic or Co-development Partner · 15 September 2025Acquisition of Laragen Sanger Sequencing business from Transnetyx, effective September 15, 2025. Expands sequencing capabilities and operations in California, strengthening presence in West Coast life sciences corridor.
• University of California-DavisminorStrategic or Co-development PartnerCooperative partner providing research collaboration and sequencing services. One of multiple academic institution partnerships in Quintara's network.
• Massachusetts Institute of Technology (MIT)minorStrategic or Co-development PartnerCooperative partner providing research collaboration and sequencing services. MIT Biology Building 68 hosts Quintara vendor events.
• National Institutes of Health (NIH)minorStrategic or Co-development PartnerCooperative partner providing research collaboration and sequencing services.
• Whitehead Institute for Biomedical ResearchminorStrategic or Co-development PartnerCooperative partner providing research collaboration and sequencing services.
• Broad Institute of MIT and HarvardminorStrategic or Co-development PartnerCooperative partner providing research collaboration and sequencing services.
• Howard Hughes Medical InstituteminorStrategic or Co-development PartnerCooperative partner providing research collaboration and sequencing services.
• Oxford Nanopore TechnologiescoreTechnology or IntegrationTechnology provider for third-generation nanopore sequencing. Quintara uses latest R10.4.1 chemistry and Oxford Nanopore platforms (MinION, PromethION) for long-read sequencing services.
• 10x GenomicscoreTechnology or IntegrationTechnology partner for single-cell sequencing services. Quintara uses latest Chromium X platform for Flex Gene Expression, Universal 3' and 5' Gene Expression assays.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Twist Bioscience: Twist is a direct peer in the DNA 'writing' layer (oligo synthesis, gene synthesis, NGS-targeted enrichment) and increasingly in antibody and DNA-data storage services. Quintara competes head-on with Twist in custom oligo/gene synthesis and NGS amplicon panels sold to research biologists.
• GenScript: GenScript is one of the closest functional analogues: gene synthesis, plasmid prep, mRNA synthesis, LNP, recombinant protein, and antibody services sold globally to academic and biotech customers at per-unit pricing. Quintara's Abgene, IVT mRNA, LNP, and HTP recombinant antibody portfolio mirrors GenScript's CDMO-style service catalog.
• Azenta Life Sciences: Azenta (formerly GeneWiz plus the combined Brooks / Brookshire / BBI businesses) runs the most directly comparable multi-modality genomics services stack: Sanger sequencing, NGS, gene synthesis, plasmid prep, and biobanking sold into the same academic and pharma researcher base. Quintara's overnight Sanger/whole-plasmid offerings on a national drop-box network mirror Azenta's long-running service model.
• Integrated DNA Technologies (IDT): IDT (a Danaher company) is the dominant specialty oligo and custom-DNA reagent vendor and also offers Sanger and NGS services. Quintara's Sanger Sequencing, gene synthesis, and QuinDye reagent product compete directly with IDT's catalog reagents and custom DNA services sold to academic genomics labs.
• Synbio Technologies: Synbio Technologies is a direct peer in gene synthesis, plasmid preparation, ORF/cDNA libraries, and protein expression services. Quintara's Abgene gene synthesis, cloning, and plasmid prep directly compete with Synbio's standard turnaround-time offerings.
• LGC Biosearch Technologies: LGC Biosearch Technologies sells custom oligos, qPCR/NGS probes, and genotyping services to the same molecular-biology researcher base. Quintara competes with Biosearch in oligos and Sanger/NGS services sold to academic and ag-biotech customers.

Emerging players

• CD Genomics: CD Genomics is an emerging competitor in NGS, single-cell, and long-read sequencing services with bioinformatics add-ons. Quintara's single-cell sequencing and Nanopore amplicon services overlap CD Genomics' catalog for academic and biotech customers.
• Blue Heron Bio (ATUM): Blue Heron / ATUM offers custom gene synthesis, plasmid construction, and protein services with a focus on gene-to-protein workflows. It is a comparable niche/emerging player for Quintara's gene synthesis and HTP recombinant antibody offerings, though smaller in scale.

Broad incumbents

• Eurofins Genomics: Eurofins Genomics is a broad incumbent offering Sanger, NGS, oligo, gene synthesis, and bioinformatics services globally through a large facility network. Quintara's DNA-read/write/produce stack overlaps Eurofins' catalog but lacks Eurofins' global reach and GLP/GMP footprint.

Others

• Boster Biological Technology: Boster is an antibody and immunoassay reagent supplier with adjacent custom protein and antibody services. It is included as an adjacent peer because Quintara's HTP recombinant antibody and bispecific antibody offerings overlap with Boster's custom antibody catalog and same customer persona.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@QuintaraBiosciences
• LinkedInlinkedin.com/company/quintara-biosciences
• Xx.com/quintara_bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quintarabio